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Abstract
Arachidonic acid (AA) is released by phospholipase A2 (PLA2) and then con-
verted into vasoactive and inflammatory eicosanoids by cyclooxygenases
(COX) and lipoxygenases (LOX). These eicosanoids are important paracrine
regulators of vascular permeability, blood flow, local pro- and anticoagulant
activity and they play a major role in the local inflammatory response. We
have investigated the presence of mRNAs for PLA2 and for isoforms of COX
and LOX in both human endothelial cells (EC) and in human smooth muscle
cells (SMC) in culture and in vascular biopsies of human umbilical veins
(HUVB) and arteries (HUAB) by using the reversed transcription-polymerase
chain reaction (RT-PCR) technique. Results show detectable levels of PLA2
type IV (cPLA2) in cultured EC and SMC and in vascular wall biopsies from
HUAB and HUVB. The cultured EC and SMC demonstrate higher levels of
both COX-1 and COX-2 with PCR analyses than do vascular wall biopsies
from HUAB and HUVB. This indicates a difference in the native expression
of COX-1 and COX-2 in cultures of EC and SMC compared to that in biopsies
from intact vessel walls. The EC and SMC in culture do not express mRNA for
5-LOX, that was, however, expressed in the vascular wall biopsies. This speaks
in favour of a constitutive, i.e. in vivo expression of 5-LOX in SMC in the
vascular wall of both umbilical vein and arteries. Thus results from in vitro
studies of constitutive COX and LOX expression in EC and vascular SMC in
culture cannot simply be extrapolated to represent in vivo conditions.
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Introduction
Phospholipase A2 (PLA2) catalyses the hydrolysis of
the sn-2 fatty acyl chain of many different phospholipids
releasing arachidonic acid (AA), which serves as a precur-
sor for the synthesis of eicosanoids. The inflammatory
and vasoactive eicosanoids are converted from AA either
by the cyclooxygenase (COX) pathway into prostaglan-
dins and thromboxane or by the lipoxygenase (LOX)
pathway into hydroperoxy-6,8,11,14 eicosatetraenoic
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acids (HPETEs) and leucotrienes. An additional potent
inflammatory mediator, platelet-activating factor may be
released if PLA2 acts on a specific phospholipid alkylacyl
glycerophosphocholine [1].
Several structurally different isoforms of PLA2 have
been defined in mammals, a 14-kD type I, type II, and a
85-kD PLA2 type IV, which preferentially hydrolyse AA-
containing phospholipids [2]. The human type I PLA2 is
found in pancreas, and probably acts as a digestive proen-
zyme [2]. Pancreatic-like PLA2 has also been found in
lung and kidney tissues, but its biological function(s) in
these tissues is not yet fully elucidated. The type II PLA2
(sPLA2) is released as a response to inflammatory media-
tors such as IL-1ß and tumour necrosis factor-· [3, 4].
This isozyme, sPLA2, is found in human synovial fluid
[5], mammalian platelets, human intestinal tissue, mono-
cytic cell lines [6] and in vascular smooth muscle cells
(SMC) [7]. The 85-kD PLA2 type IV (cPLA2) [8] is anoth-
er structurally distinct, cell-associated PLA2. This enzyme
is also active at neutral pH, Ca2+ dependent, but in con-
trast, it is very specific for the release of AA. These charac-
teristics make the 85-kD PLA2 the major liberator of AA
from phospholipids for subsequent metabolism to para-
crine lipid mediators.
In the vasculature, the synthesis of prostaglandins is
important in maintaining normal homeostasis and vascu-
lar tone. The best-known endothelium-derived anti-plate-
let and vasodilator factor is PGI2 (prostacyclin), which is
the major AA metabolite found in most endothelial cells
(EC) [9]. COX is thought to be the rate-limiting step in the
synthesis of prostaglandins by EC: two isoforms have
been identified so far, COX-1 and the recently discovered
enzyme COX-2 [10]. COX-1 was first cloned from sheep
seminal vesicles [11] and subsequently from human EC
[10]. It is considered to be constitutively expressed in
many cells [12], whereas COX-2 is highly inducible [10,
13].
The question whether human EC contain 5-LOX, 12-
LOX or 15-LOX, and thus are able to generate LTA4,
hepoxilins or lipoxins from AA, or not, is controversial.
Leucotrienes have been shown to regulate vascular per-
meability, leucocyte adhesion, and chemotaxis, as well as
smooth muscle tone. Earlier studies have shown the pres-
ence of LTB4 in both rabbit and calf aortic EC [14, 15].
On the other hand, it has been shown that LTB4 cannot be
synthesised by endogenous LTA4 because of lack of 5-
LOX [18, 19]. LTB4, however, can be produced by EC
from exogenous LTA4 [20]. Very little is known about the
ability of human SMC to produce LOX products.
The aim of this study was to investigate the gene
expression of PLA2, COX, and LOX in cultured EC and
SMC. Since the cell culture conditions may affect gene
expression in EC and SMC and as these model systems
are often used to assess in vivo conditions, we investi-
gated the presence of PLA2, COX and LOX also in native
biopsies of human umbilical arteries and veins. Reversed
transcription-polymerase chain reaction (RT-PCR), a
very sensitive method for examining mRNA in different
cell types in culture and in small tissue biopsies, was
used.
Materials and Methods
Cell Preparation
Endothelial Cells. Human umbilical venous endothelial cells
(HUVEC) were prepared as described previously by Jaffe et al. [19,
20]. The umbilical veins were first perfused with M199 culture
medium, after which it was infused with 0.1% collagenase in M199
medium. After incubation at 37°C for 15 min, the EC were flushed
from the umbilical cord vessels by perfusion, using buffer M199. The
cells were sedimented at 120 g for 5 min after which the supernatant
was removed. They were then resuspended in M199 supplemented
with gentamicin sulphate (50 mg Wml–1) fungizone (2.5 Ìg Wml–1), L-
glutamate (100 Ìg Wml–1) and 20% human serum and seeded out in
75-cm3 flasks. When grown to confluence, the cells were harvested
with 0.25% trypsin in 0.05% EDTA solution and split in a 1:3 ratio
into gelatine-coated 100-mm dishes. The dishes were incubated at
37°C under 5% CO2 in humidified air (Forma Scientific, HEPA fil-
tered IR incubator). The cells were used between passage two and
three.
Smooth Muscle Cells. Preparation of human umbilical smooth
muscle cells was performed as described previously by Okker-Reits-
ma et al. [21]. The arteries from the human umbilical cord were dis-
sected under sterile conditions and the connective tissues surround-
ing the tunica media was stripped off. The inner smooth muscle cell
layer of tunica media and tunica intima were cut into 1- to 2-mm
fragments and put into siliconized E-flasks.
The tissue biopsy was incubated in M199 at 37°C for 30 min,
supplemented with 6 mg/ml glucose, 0.1% bovine serum albumin,
0.1% collagenase (Boehringer) 2.5 ! 10–3% trypsin, gentamicin sul-
phate (50 mg Wml–1), fungizone (2.5 mg Wml–1), and 2 mg/ml elastase
under continuous shaking (70 oscillations/min). Trypsin action was
stopped by adding 15% fetal bovine serum after 60 min. Cells were
harvested by centrifugation for 5 min at 200 g and 4°C and seeded
out in flasks. The cells were used between passage four and eight.
Biopsies from Umbilical Vessels. Directly after a normal parturi-
tion, human umbilical cord arteries and vein were rinsed with iso-
tonic NaCl, dissected under sterile conditions, excised in 1-cm-long
pieces, which were immediately frozen in liquid nitrogen and stored
at –80°C until assay.
Preparation and Isolation of RNA
The biopsies from umbilical vessels and the cultured EC and
SMC were prepared using the guanidinium-thiocyanate-phenol-chlo-
roform method [22]. The RNA concentration and purity were esti-
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Fig. 1. Electrophoresis of sPLA2 (a) and
cPLA2 (b) mRNA. Expression of sPLA2
mRNA with a 326-bp fragment and cPLA2
mRNA with a 1,228-bp fragment in EC,
SMC, arterial and venous biopsies. Total
RNA was isolated and analysed by the RT-
PCR to measure the sPLA2 and cPLA2 levels
as described in Materials and Methods.
mated from the optical density at 260 and 280 nm (Perkin-Elmer,
lambda 2 UV/Vis spectrophotometer).
Reversed Transcription-Polymerase Chain Reaction
Two micrograms of total RNA from each sample was reversibly
transcribed into cDNA by incubation with 1 ÌM 15 primer, 3 mM
MgCl2, 400 U murine Moloney leukaemia virus reverse transcrip-
tase, 500 ÌM dNTP, 0.01 mM dithiothreitiol, 75 mM KCl and
50 mM Tris-HCl, pH 8.3 in a final volume of 20 Ìl at 37 °C for 1 h.
cDNA was amplified by polymerase chain reaction (PCR) in a
40-Ìl reaction containing 100 ng of transcribed total RNA, 1.25 U of
Taq DNA polymerase (Promega, Madison, Wisc., USA), 0.5 ÌM of
specific primers and 1.5 mM MgCl2 in 1 ! reaction buffer provided
by the supplier (Promega). Amplification was processed in a Perkin-
Elmer Thermal Cycler; initial heating for 2 min at 94°C, followed by
25–32 cycles of 1 min at 94°C, 1 min at 60°C, 2 min at 72°C and a
final extension for 7 min at 72°C.
Ten microlitres of the reaction mixture were mixed with loading
buffer and separated by electrophoresis on 1.2% agarose gels contain-
ing ethidium bromide (0.5 Ìg/ml) and visualised by UV transillumi-
nation.
PCR Primers
cDNA from each sample was amplified with specific primers for
sPLA2, cPLA2 COX-1, COX-2, 5-LOX, 12-LOX and 15-LOX in sep-
arate tubes. The forward and reverse primers for sPLA2 were:
5)-GACGACAGGAAAGGAAGCC-3) and 5)-TCCCTCTGCAGT-
GTTTATTGG-3), respectively, and gave a single band correspond-
ing to a 326-bp fragment in human sPLA2 cDNA [23]. The forward
and reverse primers for cPLA2 were: 5)-CCTGATATGGAGAA-
AGATTGCC-3) and 5)-AGGGAAACAGAGCAACG-AGA-3), re-
spectively, and gave a single band corresponding to a 1,228-bp frag-
ment in human cPLA2 cDNA [24].
The forward and reverse primers for COX-1 were: 5)-TGCCCA-
GCTCCTGGCCCGCCGCTT-3) and 5)-GTGCATCAACACAGG-
CGCCTCTTC-3), respectively, and gave a single band correspond-
ing to a 306-bp fragment in human COX-1 cDNA [10].
The recently described forward and reverse primers for COX-2
were: 5)-TTCAAATGAGATTGTGGGAAAATTGCT-3) and 5)-
AGATCATCTCTGCCTGAGTATCTT-3), respectively, and gave a
single band corresponding to a 307-bp fragment in human COX-2
cDNA [10]. The forward and reverse primers for 5-LOX were:
5)-TGCTTTCCCGAGGCCATCAAGG-3) and 5)-GCTTCCTTC-
ACAGGCTTCTCGATA-3), respectively. These yielded a single
PCR product corresponding to a 557-bp fragment in human cDNA
[25].
The forward and reverse primers for 12-LOX were: 5)-CCACCT-
CTTCTACCAAAGGGATG-3) and 5)-AATCTGTTCGGAATTG-
GTTTAGCAC-3), respectively. These yielded a single PCR product
corresponding to a 459-bp fragment from human cDNA [26].
The forward and reverse primers for 15-LOX were: 5)-AAT-
CGTGAGTCTCCACTATAAGAC-3) and 5)-AGCCAGCTCCTC-
CCTGAACTTCT-3), respectively. These yielded a single PCR prod-
uct corresponding to a 466-bp fragment in human cDNA [27].
Results
In this study we used RT-PCR to examine gene expres-
sion of mRNA for cPLA2, sPLA2, COX-1, COX-2, 5-
LOX, 12-LOX and 15-LOX in EC, SMC and in biopsies
from umbilical arteries and veins. This technology is
extremely sensitive and allows the monitoring of mRNA
levels from small amounts of total RNA. RNA samples
that were not processed with reversed transcriptase gave
no detectable PCR product (result not shown).
In cultured EC, only high-molecular-weight cytosolic
PLA2 was expressed at detectable levels (fig. 1). Further-
more, five different oxygenases, representing key enzymes
for the downstream metabolism of AA for the production
of specific lipid messengers, were analysed. Clear expres-
sion of COX-1 and COX-2 mRNA was found in EC
(fig. 2). However, no mRNA for the leucotriene synthesis
pathway 5-LOX and 12-LOX or of 15-LOX mRNA could
be detected (fig. 3).
In cultured SMC, cPLA2 gene expression was evident
in analogy to the EC in culture. However, small amounts
of sPLA2 mRNA were also consistently observed in these
cells (not visible on the gel presented in fig. 1a). Similar to
the findings in EC, significant levels of COX-1, COX-2
mRNA were expressed (fig. 2). The mRNA expressions of
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Fig. 2. Electrophoresis of COX-1 (a) and
COX-2 (b) mRNA. Expression of COX-1
mRNA with 306-bp fragment and COX-2
mRNA with a 307-bp fragment in EC, SMC,
arterial and venous biopsies. Total RNA was
isolated and analysed by the RT-PCR to
measure the COX-1 and COX-2 levels as
described in Materials and Methods.
Fig. 3. Electrophoresis of 5-LOX (a), 12-
LOX (b) and 15-LOX (c) mRNA. Expres-
sion of 5-LOX mRNA with a 557-bp frag-
ment, 12-LOX mRNA with a 459-bp frag-
ment and 15-LOX mRNA with 466-bp frag-
ments in EC, SMC, arterial and venous biop-
sies. Total RNA was isolated from respective
samples and analysed by the RT-PCR to
measure the 5-LOX, 12-LOX and 15-LOX
levels as described in Materials and Meth-
ods.
5-LOX and 15-LOX were missing, whereas very small
amounts of 12-LOX was found in SMC (fig. 3b).
In analogy to cultured SMC and EC, we found signifi-
cant levels of cPLA2 mRNA in the vascular biopsies
(fig. 1). In contrast to the findings in cultured cells, we also
found high levels of mRNA for sPLA2 in the biopsies of
tunicae mediae from umbilical arteries and veins. Fur-
thermore, very small levels of COX-1 and COX-2 mRNA
were expressed in biopsies of human umbilical arteries
(HUAB) and veins (HUVB) (fig. 2b).
The most notable difference between cultured EC and
SMC and the same cells in umbilical vessel wall biopsies
was the gene expression of 5-LOX in the latter (fig. 3).
This was significantly expressed in both HUAB and
HUVB, but not in EC and SMC in culture, where no
detectable levels of 5-LOX mRNA were expressed. No
detectable levels of 12-LOX or 15-LOX were found in
either HUAB or HUVB.
Discussion
Both SMC and EC are known to contain PLA2 [28, 29].
The former have been shown to mainly contain the sPLA2
[30], which is in agreement with our results. In addition,
we have found significant expression of mRNA for cPLA2
in both SMC and EC. Recently, it was shown that stimula-
tion of bovine EC with bradykinin increases the activity
of a [Ca2+]-sensitive high-molecular PLA2 [31]. Further,
IL-1ß and transforming growth factor-ß have been shown
to induce expression of cPLA2 mRNA in calf pulmonary
artery EC in a concentration-dependent fashion [32].
Since recombinant human tumour necrosis factor and
human IL-1ß rapidly increase PLA2 activity [29], this
could indicate that cPLA2 is post-transcriptionally regu-
lated by these agents and, thus, probably constitutively
expressed in these cells.
Our investigations of the COX-1 and COX-2 showed
significant levels of COX-1 and COX-2 in both EC and
SMC, which is in agreement with former investigations
[32, 33]. COX-2 is reported to be induced only after cyto-
kine stimulation [34]. However, some recent reports
found it to be highly expressed in EC without any cyto-
kine stimulation [35, 36]. In accordance with the differ-
ence in the expressions in actively proliferating SMC and
EC in in vitro cultures in mature, non-synthesising, non-
cycling corresponding cell types in cells in biopsies from
vessel walls in this study, such discrepancies could depend
on growth conditions, i.e. serum factors and number of
passages. However, in vascular biopsies no, or minute
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amounts of mRNA for COX-1 or COX-2 were present.
This may indicate that the isoforms of COX investigated
in this study are not involved in normal, paracrine vascu-
lar regulation, but may be induced under pathophysiolog-
ical conditions such as inflammation or angiogenesis.
Contradictory results concerning the presence of 5-
LOX in EC have also been reported. Thus, whether or not
a constitutive production of LTA4 and the other leuco-
trienes occur in these cells is controversial at present. In
aortic and other arterial EC from various animals, 5-, 12-,
15-HETE and LTB4 have been identified, demonstrating
a constitutive expression of 5-, 12- and 15-LOX activity
in EC at these locations [14, 15, 37, 38]. However, the
presence of 5-LOX in HUVEC has not been reported.
Hopkins et al. [16] have demonstrated the presence of 15-
HPETE and 8,15-di-HETE in HUVEC, but not 5-HETE
or LTA4. Johnsson et al. [39] have shown that EC can
metabolise, but not synthesise leucotrienes. These results
are in agreement with our results. While in our study we
have found an expression of 5-LOX mRNA in both
HUAB and HUVB, we cannot exclude the possibility that
the observed differences between cultured cells and vessel
biopsies could be due to contamination of mRNA from
non-vascular cells, normally residing within the walls of
human umbilical veins and arteries. Histologic [40] and
electron-microscopic [41] studies have shown the pres-
ence of lymphocytes and monocytes within the arterial
intima from other vascular locations than the umbilical
vessels. The methods used in our study only reflect the
mRNA levels for the specific enzymes. For COX it has
been demonstrated that the mRNA level correlates with
the level of protein and prostaglandin produced [34, 36].
It may then be pertinent to assume that the presence or
absence of specific mRNA in a particular cell type, either
under in vitro or in vivo conditions, also generally corre-
lates with the presence or absence of the protein.
In summary our investigation indicates that there is a
different expression of mRNA for COX-1, COX-2 and 5-
LOX in native biopsies of blood vessel walls and in cul-
tured vascular cells isolated from the same vessels. Even
though the RT-PCR method cannot be used to quantita-
tively assess tissue concentrations of specific mRNA, our
results do disclose not only a qualitative difference of
expressions in the same cell type – ECs and SMCs – but
also a quantitative difference, depending on whether they
are in an actively cycling/protein synthesising mode or
in the non-cycling state in the mature vessel wall. For
COX-1 and COX-2, hardly any mRNA was found in the
umbilical blood vessel biopsies, in contrast to results from
SMC and EC from the same vessels in culture. There the
cDNA fragments for both COX-1 and COX-2 were easily
detected with the RT-PCR technique. mRNA for 5-LOX
was not expressed at all in the cultured vascular cells, but
was regularly detected in all vascular biopsies. These dif-
ferences most probably reflect the difference of expres-
sions of nuclear and other factors between the two states.
However, these differences indicate the necessity to be
careful when extrapolating results from in vitro experi-
ments with EC and SMC in culture to in vivo or to clinical
conditions.
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